|
Core Support for Cancer Center
|
3P30CA013330-39S1
|
$249,624
|
$4,992
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S2
|
$249,624
|
$4,992
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S3
|
$74,922
|
$1,498
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
5P30CA013330-39
|
$3,725,702
|
$74,514
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
The role of c-Maf in Stem cells in Leukemia
|
1F31CA162770-01
|
$41,800
|
$20,900
|
Okoye, Ujunwa
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Mismatch repair in V region mutation and isotype switching
|
5R01CA102705-08
|
$314,906
|
$157,453
|
SCHARFF, MATTHEW
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Transcriptional regulation of leukemic stem cells in acute myeloid leukemia
|
5R00CA131503-04
|
$241,530
|
$241,530
|
Steidl, Ulrich
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
SATB1-dependent epigenetic regulation of leukemia initiating cells
|
1F32CA162930-01
|
$51,326
|
$51,326
|
Will, Britta
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Tunable DNA-nanostructure to induce NK-mediated killing of tumor cells
|
5R21CA141021-02
|
$154,564
|
$77,282
|
CHANG, YUNG
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-22
|
$406,165
|
$36,555
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Enhancing Treg Immune Reconstitution After Stem Cell Transplant
|
1R21CA149967-01A1
|
$325,834
|
$325,834
|
BOLLARD, CATHERINE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-05S1
|
$75,000
|
$3,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-05
|
$2,934,758
|
$117,390
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Pediatric Clinical Oncology Research Training Program
|
3K12CA090433-10S1
|
$134,042
|
$53,617
|
Poplack, David
|
BAYLOR COLLEGE OF MEDICINE
|
|
Pediatric Clinical Oncology Research Training Program
|
5K12CA090433-10
|
$475,607
|
$190,243
|
Poplack, David
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mechanism and Consequences of Telomere Dysfunction
|
5R01CA133249-04
|
$308,957
|
$154,479
|
Songyang, Zhou
|
BAYLOR COLLEGE OF MEDICINE
|
|
SELECTIVE MITOCHONDRIAL AUTOPHAGY IN THE MAINTENANCE OF GENOME STABILITY
|
5R21CA152076-02
|
$198,106
|
$198,106
|
WANG, JIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting PML for therapy in leukemia-initiating cells
|
5K99CA139009-02
|
$89,144
|
$89,144
|
Ito, Keisuke
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Novel Strategies for Treatment of Myeloproliferative Disorders
|
5R01CA131664-04
|
$368,268
|
$368,268
|
KHOSRAVI-FAR, ROYA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting PML for leukemia therapy.
|
5R01CA142874-02
|
$457,498
|
$457,498
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Dendritic Cell/Leukemia Fusions and PD-1 Blockade for AML
|
5R21CA149987-02
|
$350,407
|
$350,407
|
ROSENBLATT, JACALYN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Distinct acute myeloid leukemia subclasses with CEBPA mutations
|
5R01CA118316-05
|
$397,021
|
$397,021
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting Leukemic Stem Cells
|
5R01CA138211-04
|
$419,335
|
$419,335
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Rapid Testing of Drug-Resistant BCR-ABL(+)Leukemia Cells
|
1R43CA153614-01A1
|
$199,691
|
$199,691
|
Rieder, Ronald
|
BIOSENSE TECHNOLOGIES, INC.
|
|
Cancer and Leukemia Group B Human Specimen Repositories
|
2U24CA114725-07
|
$846,033
|
$423,017
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B
|
3U10CA031946-30S1
|
$3,449,605
|
$448,449
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B Human Specimen Repositories
|
3U24CA114725-06S1
|
$309,562
|
$154,781
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B
|
5U10CA031946-30
|
$10,820,362
|
$1,406,647
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B CCOP Research Base
|
5U10CA037447-27
|
$2,389,751
|
$143,385
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Enabling Technologies for MRI-Guided Prostate Interventions
|
2R01CA111288-06
|
$673,188
|
$673,188
|
TEMPANY, CLARE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
To establish the BC Cancer Agency - Vancouver Centre as a major SWOG centre
|
5U10CA142559-02
|
$188,304
|
$1,883
|
BLANKE, CHARLES
|
BRITISH COLUMBIA CANCER AGENCY
|
|
Broad Institute Center for Cancer Systems Biology
|
5U54CA112962-07
|
$2,032,718
|
$508,180
|
GOLUB, TODD
|
BROAD INSTITUTE, INC.
|
|
Bcl-2 function on the endoplasmic reticulum
|
5R01CA085804-12
|
$284,448
|
$142,224
|
DISTELHORST, CLARK
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
|
5U01CA062502-18
|
$746,424
|
$44,785
|
DOWLATI, AFSHIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Pax5:Hematopoietic Transcription Factor Involved in ALL
|
5R01CA026038-32
|
$365,285
|
$365,285
|
koeffler, Harold
|
CEDARS-SINAI MEDICAL CENTER
|
|
Exploiting synthetic lethality of hematopoietic lineage cells to develop novel ta
|
2R44CA141848-02
|
$941,894
|
$470,947
|
Bonneau, Kyle
|
CELLECTA, INC.
|
|
Phase I SBIR TOPIC 307 PET Imaging of Activated T cells During Cancer Treatment
|
N43CO110119-000
|
$247,568
|
$123,784
|
YAGHOUBI, SHAHRIAR
|
CELLSIGHT TECHNOLOGIES, INC.
|
|
Molecular pathogenesis of MLL-AF4 leukemias
|
5R01CA140575-02
|
$347,535
|
$347,535
|
ARMSTRONG, SCOTT
|
CHILDREN'S HOSPITAL BOSTON
|
|
The role of AF10 in normal and leukemic hematopoiesis
|
1K99CA154880-01A1
|
$153,117
|
$153,117
|
DESHPANDE, ANIRUDDHA
|
CHILDREN'S HOSPITAL BOSTON
|
|
Autophagy and apoptosis in the response of c-KIT cancers to targeted therapy
|
1K08CA154782-01A1
|
$143,362
|
$71,681
|
GORDON, PETER
|
CHILDREN'S HOSPITAL BOSTON
|
|
The role of Hedgehog in hematopoiesis and leukemogenesis
|
5K08CA140723-02
|
$168,588
|
$168,588
|
Hofmann Zhang, Inga
|
CHILDREN'S HOSPITAL BOSTON
|
|
Ezh2 in MLL-AF9 mediated acute myeloid leukemia
|
1K08CA154777-01
|
$146,016
|
$146,016
|
Neff, Tobias
|
CHILDREN'S HOSPITAL BOSTON
|
|
RhoH GTPase in Hematopoiesis and Cancer
|
5R01CA113969-07
|
$323,678
|
$161,839
|
WILLIAMS, DAVID
|
CHILDREN'S HOSPITAL BOSTON
|
|
Center for Environment-Mediated Drug Resistance in Pediatric Cancer
|
1U54CA163117-01
|
$503,090
|
$251,545
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs
|
5R01CA090321-10
|
$258,678
|
$258,678
|
HEISTERKAMP, NORA
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Investigating the Role of Adipocytes on Leukemia Relapse
|
5R01CA139060-03
|
$322,443
|
$322,443
|
Mittelman, Steven
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Infectious origins of childhood leukemia
|
1R01CA157644-01
|
$332,000
|
$332,000
|
Muschen, Markus
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Pre-B cell receptor signaling in acute lymphoblastic leukemia
|
5R01CA137060-03
|
$322,040
|
$322,040
|
Muschen, Markus
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia
|
5R01CA139032-03
|
$322,040
|
$322,040
|
Muschen, Markus
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Mechanism of BCL6-dependent stem cell maintenance in B cell lineage leukemia
|
5R21CA152497-02
|
$168,781
|
$168,781
|
Muschen, Markus
|
CHILDREN'S HOSPITAL LOS ANGELES
|
Total relevant funding to Leukemia for this search: $227,025,963
|